Key facts
- Notable investors include Dorm Room Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Kalevala Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Kalevala Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kalevala Therapeutics
Developer of rare disease drug repurposing therapies based in the United States. The company identifies existing drugs with credible evidence for new use in underserved rare indications and advances them through programs built around collaboration with industry partners, clinicians, and patient advocates, providing a structured process for mapping regulatory pathways and seeking approvals, enabling patients with rare diseases and limited treatment options to gain access to repurposed therapeutics targeting unmet medical needs
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2025
- Employees
- 2
- Website
- kalevalatherapeutics.com/
- Ownership
- Privately Held (backing)
Kalevala Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kalevala Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kalevala Therapeutics in its N-PORT filings yet. We sweep new filings monthly.